Fitzsimons Innovation Community is an integrated urban campus where health and life sciences companies of all sizes work on their next big things. Our customized workspace, collaborative campus, and proximity to one of the top health systems and medical schools in the country make our community the perfect place to put down roots and get to work.
MOVE-IN READY LAB SPACE
GROWTH OPPORTUNITIES
It’s not just additional space—it’s fifty sprawling acres of additional space. And it’s primed for ultra-custom, made-to-order facility development.
Fitzsimons Innovation Community and University of Colorado Anschutz Medical Campus working together.
Relationships that help you thrive.
FEATURED:
One of the most exciting times of year for us here at Fitzsimons Innovation Community is when we launch our Annual Innovation Report, and this year is no different. For the fourth year in a row, we are proud to share this report featuring updates, insight, and data about all the things that make our Community special.
Fitzsimons Innovation Community is where innovators come to turn ideas into business.
A regular feature of a Fitzsimons Innovation Community visionary.
Our year in innovation.
Find out what’s happening on campus and across the industry.
An urban mountain lifestyle for work and play.
Everything you need.
Right here.
Read Fitzsimons Innovation Community news, industry highlights, editorials, and innovation updates happening weekly on our campus.
As we close out this milestone year celebrating our 25th anniversary, we've been reflecting on the incredible journey from visionary concept to thriving hub of health and life sciences innovation. Throughout 2025, we've shared fun insights on social media about the lessons learned, the a-ha moments discovered, and the collective wisdom gathered from the brilliant minds who call our Community home. Now, we're bringing all the fun together in one place—a celebration of what makes Fitzsimons Innovation Community truly special.
The Global Business Development division of the Colorado Office of Economic Development and International Trade (OEDIT) announced that 17 Colorado companies and eight researchers have been awarded Proof of Concept and Early-Stage Capital and Retention grants through OEDIT’s Advanced Industries Accelerator Program. Congratulations to the Fitzsimons Innovation Community Early-Stage Capital and Retention Grant Recipients: Onconaut Therapeutics, Inc., Vega Surgical, Inc., and Vona Oncology LLC.
UCHealth said it's the first in Colorado to offer a kind of mammogram that could be a game changer when it comes to detecting breast cancer. Dr. Elizabeth Vorhis, a breast radiologist said she uses an IV contrast during a mammogram. It's the same kind of process if you go to the emergency room and get a stomach or chest CT scan.
Colorado BioScience Association (CBSA) announced the winners of its 22nd Annual Awards Celebration, recognizing the people and organizations advancing Colorado’s position as a leading hub for health innovation. The awards spotlight leaders whose work accelerates breakthrough discoveries and delivers impact for patients in Colorado and around the world. Dr. Katherine Goodman, Associate Professor at the University of Colorado Denver | Anschutz, received the Educator of the Year Award for her outstanding contributions to shaping Colorado’s future life sciences workforce. EnteroTrack and RheumaGen were honored as Rising Star of the Year finalists.
Earlier this year, Kate Goes became the first patient in North America to use FDA-approved adaptive deep brain stimulation (DBS) technology for Parkinson’s. UCHealth Ph.D. clinical neuropsychologist John Thompson helped make the pathbreaking innovation possible.
Earlier this year, Kate Goes became the first patient in North America to use FDA-approved adaptive deep brain stimulation (DBS) technology for Parkinson’s. UCHealth Ph.D. clinical neuropsychologist John Thompson helped make the pathbreaking innovation possible.
Earlier this year, Kate Goes became the first patient in North America to use FDA-approved adaptive deep brain stimulation (DBS) technology for Parkinson’s. UCHealth Ph.D. clinical neuropsychologist John Thompson helped make the pathbreaking innovation possible.
The University of Colorado system generated $12.2 billion in economic impact across Colorado last year, highlighting CU’s growing role in the state’s economy through education, research, innovation and health care, according to a new economic study. This is growth of more than half a billion dollars over 2024.
When Israel Villaseñor, Chief Strategy Officer of IMD Path, talks about his company's journey to Colorado, he uses a word that perfectly captures how it all happened: serendipitous. What started as a California-focused molecular diagnostics company has found a true home right here at Fitzsimons Innovation Community. "If it wasn't for networking and having connections, we would have never known about Fitzsimons," Villaseñor reflects. "We would have probably ended up just locking ourselves into California and not thinking about Colorado."
Colorado Real Estate Journal's latest Health Care and Life Sciences Quarterly features an article from Dr. Terry Fry, Executive Director of the Gates Institute at University of Colorado Anschutz, about how the proximity between academia, biomanufacturing, and industry collaboration at Fitzsimons accelerates the development of life-changing cell and gene therapies.
Precision health and medicine giant Verily will be partnering with CU Anschutz and UCHealth to create an AI enabled ecosystem entailing research ready biomedical pipelines and datasets. In addition, the partnership is aiming to build curated AI models across a variety of specific therapeutic and drug areas, such as oncology, musculoskeletal and transplant medicine, to name a few. All of this work will be done using CU Anschutz’s vast research datasets via Verily Workbench, one of the company’s flagship products.
RheumaGen, Inc. and SiVEC Biotechnologies, Inc. today announced a licensing and joint development agreement for a breakthrough class of gene-editing therapies designed to cure autoimmune diseases. The partnership will utilize SiVEC's BactPac™ drug delivery platform to streamline manufacturing and increase scalability of RheumaGen's new class of human leukocyte antigen (HLA) gene-editing therapies for common autoimmune diseases; importantly, the partnership also establishes an in vivo program that will be co-developed by the companies.
Fitzsimons Innovation Community
